GI Pancreatic - Metastatic

Quality Improvement Trials:
- IRB # 22619: A Phase II Trial of Preoperative Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula following Distal Pancreatectomy
- IRB # 22413 Polyglycolic Acid Mesh to Prevent Pancreatic Fistula After Distal Pancreatectomy: A Multi-Center Efficacy Trial

First Line Treatment for Advanced or Metastatic Pancreatic Cancer
- IRB# 17751 Trans(Intra)-arterial Gemcitabine vs. Continuation of IV Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Cancer
- IRB# 17094 A Phase Ib/II Trial of Preoperative Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula following Distal Pancreatectomy
- IRB#23315 A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumours
- IRB#23124 A Phase 1b/2 Randomized Study of AVB-S6-500 plus Nab-Paclitaxel and Gemcitabine in Patients with Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma

Second Line Treatment for Advanced or Metastatic Pancreatic Cancer
- IRB# 17094 A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Third Line Treatment for Advanced or Metastatic Pancreatic Cancer
- IRB# 17094 A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

Cross-Disease Trials:
- IRB# 20679 Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment
- IRB# 19211 A Feasibility Study to Assess a Window of Opportunity Strategy for Targeted PARP or MEK Inhibition in Patients with Pancreatic Ductal Adenocarcinoma
- IRB# 17751 NeoAdjuvant: A Phase Ib/II Trial To Assess The Efficacy Of Adaptive Switching Of mFolfirinox Or Gemcitabine/Nab-Paclitaxel As A NeoAdjuvant Strategy For Patients With Resectable And Borderline Resectable Pancreatic Cancer.